In:
Intervirology, S. Karger AG, Vol. 53, No. 3 ( 2010), p. 146-153
Abstract:
〈 i 〉 Objectives: 〈 /i 〉 The authors compared the efficacies and tolerabilities of pegylated interferon-α 〈 sub 〉 2a 〈 /sub 〉 (PEG-IFN-α 〈 sub 〉 2a 〈 /sub 〉 ) + ribavirin and pegylated interferon-α 〈 sub 〉 2b 〈 /sub 〉 (PEG-IFN-α 〈 sub 〉 2b 〈 /sub 〉 ) + ribavirin for the initial treatment of chronic hepatitis C. 〈 i 〉 Methods: 〈 /i 〉 A total of 126 treatment-naive patients (29.4% genotype 1, 70.6% genotype non-1) were treated with PEG-IFN-α 〈 sub 〉 2a 〈 /sub 〉 180 µg/week (group A, n = 79) or PEG-IFN-α 〈 sub 〉 2b 〈 /sub 〉 1.5 µg/kg/week (group B, n = 47) with ribavirin (800 mg/day for genotype non-1 or 1,000–1,200 mg/day for genotype 1) for 24 (genotype non-1) or 48 weeks (genotype 1). 〈 i 〉 Results: 〈 /i 〉 End-of-treatment virologic response, sustained virologic response, and biochemical response were not significantly different in groups A and B (84.8 vs. 89.4%, 70.9 vs. 72.3%, and 70.9 vs. 74.5%, respectively; p 〉 0.05). In patients with the HCV genotype 1 or non-1, treatment responses were not significantly different. Multivariate analysis showed that HCV genotype only was an independent factor that affected sustained virologic response (p = 0.048). The proportions of treatment discontinuations in groups A and B were similar (10.1 vs. 10.6%; p = 1.000). 〈 i 〉 Conclusions: 〈 /i 〉 PEG-IFN-α 〈 sub 〉 2a 〈 /sub 〉 or PEG-IFN-α 〈 sub 〉 2b 〈 /sub 〉 + ribavirin combination therapies showed similar efficacies and tolerabilities as initial treatments for chronic hepatitis C.
Type of Medium:
Online Resource
ISSN:
0300-5526
,
1423-0100
Language:
English
Publisher:
S. Karger AG
Publication Date:
2010
detail.hit.zdb_id:
1482863-7
SSG:
12
Bookmarklink